

Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study

N. HOEPFFNER^{*1}, Y. M. SHASTRI^{*1}, E. HANISCH[†], W. RÖSCH[‡], J. MÖSSNERS, W. F. CASPARY^{*} & J. STEIN^{*}

^{*}Department of Medicine I, ZAFES, Centre of Internal Medicine, Johann Wolfgang Goethe University, Frankfurt/Main; [†]Asklepiosklinik, Dreieich-Langen; [‡]Department of Medicine II, Hospital Northwest, Frankfurt/Main; [§]Department of Medicine II, University Hospital Leipzig, Leipzig, Germany

Correspondence to:
Dr J. Stein, Department of Medicine I, ZAFES, J. W. Goethe University Frankfurt, Theodor-Stern-Kai 7, D – 60590 Frankfurt/Main, Germany.
E-mail: j.stein@em.uni-frankfurt.de

¹These authors contributed equally to this study.

Publication data

Submitted 23 August 2005
First decision 12 September 2005
Resubmitted 29 September 2005
Accepted 29 September 2005

SUMMARY

Background

Faecal occult blood testing is an established method of colorectal neoplasia screening. Guaiac-based tests are limited by poor patient compliance, low sensitivity, specificity and positive predictive value. Newer immunochemical-based tests, accurate but tedious, require a well-established laboratory set up. There is need for simpler immunochemical tests that can be performed at the out-patient clinic.

Aim

To compare the performance characteristics of a new bedside immunological test strip device with a sensitive Guaiac-based and established immunochemical test for detection of faecal occult blood in patients undergoing colonoscopy.

Methods

A total of 389 consecutive patients from four centres who were referred for colonoscopy also provided the stool samples for detection of occult blood without dietary restrictions. Stool tests performed were (i) Guaiac-based, (ii) immunochemical enzyme-linked immunosorbent assay and (iii) bedside immunochemical strip test.

Results

At the optimal threshold level, the sensitivity and specificity of the bedside immunochemical strip test for detection of significant colorectal neoplasia (adenomas >1.0 cm and carcinomas) were 60% and 95%, respectively.

Conclusions

This bedside immunochemical strip test proved to be a simple, convenient, non-cumbersome and accurate tool with similar performance characteristics for detection of any bleeding lesion including colorectal neoplasia when compared with an established immunochemical faecal occult blood test.

Aliment Pharmacol Ther 23, 145–154

INTRODUCTION

Colorectal cancer (CRC) accounted for about 1 million new cases in 2002; its worldwide prevalence is only second to that of breast cancer. It is one of the leading causes of cancer death in western societies with 25-fold variation in its occurrence across the globe.¹ In Europe, there were estimated to be 376 400 new cases of CRC amounting to 203 700 deaths in 2004² while in the US there are expected to be 145 200 CRC registrations and 56 290 deaths this year.³ It is estimated that about half of these deaths could have been prevented if patients would have undergone CRC screening.⁴ It has been observed that most cases of sporadic CRC arise from pre-existing adenomatous polyps.

The metastatic CRC [stage IV tumour node metastasis (TNM)] has a dismal survival of <5% when compared with early CRC (stage I TNM).⁵ The prevalence of the disease, with the proven ability of screening to reduce mortality makes population-wide screening of CRC a lucrative health goal. An ideal screening test must be non-invasive, acceptable to patients, simple, have high sensitivity and specificity, inexpensive, cost-effective, easy to implement across a large population and should be effective in reducing morbidity and mortality from CRC in the screened population.⁶

The most widely accepted non-invasive method for detecting CRC is faecal occult blood testing (FOBT). It is routinely used world over for CRC screening and surveillance and has been in use now for more than three decades. Screening in asymptomatic populations with FOBTs followed by colonoscopy if tested positive have reduced mortality rates by 15–33%.^{7–10} However, sensitivity of FOBTs ranges from 26% to 69% for detecting CRC.^{11–14}

There are two main types of commercially available FOBTs: 'Guaiac-based tests' in which Guaiac blue colour change occurs because of the pseudoperoxidase activity of haeme in the stool; 'immunochemical tests' which detect globin portion of human haemoglobin (Hb) in the stool using anti-Hb antibodies.¹⁵ A major disadvantage of Guaiac tests is the fact that they are not specific for human blood and can produce false-positive results when meat, fruit, or vegetables containing peroxidase have been ingested. Also bleeding in the upper gastrointestinal (GI) tract secondary to aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) can produce false-positive Guaiac-based tests.¹⁶ This may lead to contraindicate colonoscopic examinations thus increasing the cost and risk of

screening programmes. False-negative tests may occur with ingestion of high doses of vitamin C, which will prevent detection of cancer and will provide a false sense of security to the patient. Because of these shortcomings Guaiac-based tests are being replaced by immunochemical faecal occult blood tests (IFOBTs), despite being more expensive.

The IFOBTs, which are widely used as screening tests in Japan, have been shown to be superior to the Guaiac-based tests in sensitivities, with similar specificity, as reported both in known CRC¹⁷ and in asymptomatic populations.^{13, 18} This is because IFOBTs do not detect blood from the upper GI tract, do not react with plant peroxidases and animal Hb. Thus, there is no need of dietary or medical restriction. One of the studies has shown 66% increase in patient participation with the elimination of dietary restrictions.¹⁹ Furthermore, sensitivity of IFOBTs is high for adenomas,¹⁷ intramucosal cancer²⁰ and Dukes A cancer.²¹ On the basis of these reports, it is expected that screening with IFOBTs may provide larger effects on the incidence reduction of advanced CRC when compared with the Guaiac-based tests. However, most IFOBTs require a suitable well-equipped laboratory, i.e. an enzyme-linked immunosorbent assay (ELISA) reader, limiting their widespread use because of logistics and higher costs.

Colonoscopy is considered the gold standard for CRC screening. But it is expensive, requires skilled endoscopist and may lead to life-threatening complications like perforation (one in 300 procedures).²² However, complication rate varies in different studies and one of the recent studies in which more than 22 000 patients underwent screening colonoscopies (only diagnostic) by experienced endoscopists without any major complication or mortality.²³

In a recent pilot study, we demonstrated a new immunological test strip device (bedside IFOBT) for the rapid, quantitative detection of FOB (Prevent ID CC, Preventis GmbH, Bensheim, Germany) and compared it with a widely used Guaiac-FOBT keeping ELISA-IFOBT as the gold standard. We showed that this bedside IFOBT is much more sensitive (76% vs. 30%) for detection of FOB than Guaiac-based test whereas specificity of both tests were comparable.²⁴ However, we did not perform colonoscopy in these patients.

In the present prospective study, we have evaluated the performance characteristics of this new bedside test for detection of FOB in patients undergoing colonoscopy. Experienced endoscopists carefully examined

the entire large bowel, recorded and reported the presence of any bleeding lesion that could cause positive FOBT. If any such lesion was found it was biopsied or snared if indicated. We also compared it with another established IFOBT (ELISA) and a sensitive Guaiac-based FOBT.

Our study is peculiar and different from previous studies in that the patient population was not only of CRC screening patients but also constituted the patients referred to or admitted with colonic symptoms and many of them had known clinical diagnosis. Thus, we evaluated performance characteristics of FOBT not only in detecting neoplasia but also in detecting presence of microscopic faecal blood whether it was because of neoplasia, inflammatory bowel disease (IBD) or dysentery.

MATERIAL AND METHODS

Ethics

The study protocol was approved by the ethics committee of Frankfurt University Hospital. Written informed consent was obtained from all participants before entering the study.

Patients and healthy controls

Patients from four different centres who were referred for colonoscopy were invited to participate in the study. There were 237 patients who either had known clinical diagnosis (e.g. IBD) or were symptomatic suggestive of colonic disease while as 150 healthy patients underwent CRC screening. Patients with active GI bleeding, menstruation and past history of total colectomy were not included in the study.

Patients given appointments for colonoscopy were asked to provide one stool sample for detecting faecal blood. No dietary restrictions were advised to the patients. Stool sample was collected before starting the bowel preparation in a sterile box for Guaiac and immunological tests whereas for the bedside IFOBT we provided patients with a simple stool-collecting device (see below). Stool samples of these patients with or without pathological findings were tested. In a standard questionnaire patient's clinical history was recorded.

After standard bowel wash colonoscopies were performed by the endoscopists, who were not aware of FOBT findings, till the caecum using the standard col-

onoscopes. Patients who were poorly prepared or in whom caecum could not be reached were not included in the study. Histology was obtained from the routine biopsies, polypectomies and/or from surgery. Adenomas were classified as large (>10 mm) or small (<10 mm) as judged during colonoscopies using biopsy forceps as measure to assess polyp size. All data were collected prospectively and recorded on standardized questionnaire forms. If a neoplastic obstructive lesion was found during colonoscopies, it was biopsied and the patient was included in the study despite colonoscopy not being complete.

Faecal occult blood tests

Stool samples were applied to the three windows of a Guaiac-FOBT Haemoccult (Beckman Coulter, Inc., Fullerton, CA, USA) and further processed without rehydration as indicated by the manufacturer. On an especially Guaiac resin impregnated filter paper stool sample was placed. Once it had dried alcohol-stabilized hydrogen peroxide was put on the paper. A positive test was indicated by colour change to blue after 60 s.

A human Hb ELISA (Immundiagnostik AG, Bensheim, Germany) was used as a highly sensitive IFOBT. This test is based on Hb antibodies-precoated microtitre plates. To 100 mg of faeces wash buffer was added, mixed and centrifuged. About 100 L of this solution was incubated on the microtitre plates precoated with anti-Hb antibodies. After washing anti-Hb a peroxidase-labelled antibody was added, and was incubated for 1 h. Then, the substrate was added and incubated for 20 min and finally the stop solution was added so the colour changed from blue to yellow. Absorption was determined with an ELISA reader at 450 nm against reference value. According to the manufacturer a cut-off level of ≤ 10 g Hb/mL of stool was used.

An immunological FOB test strip device (Prevent ID CC) was used. It is a one-step immunochromatographic assay for rapid quantitative detection of human faecal blood. One of its major advantages, which should make it more acceptable to the patients, is the simplicity and non-messy sample collection. Figure 1 demonstrates the convenience of this test. The stick of the sample collection device was stuck into the faeces (approximately 2 cm), it was then inserted into the collection device containing an extraction buffer solution and the assembly was shaken thoroughly. This procedure was repeated three times sampling the




Figure 1. Sample collection for the bedside immunochemical faecal occult blood test (IFOBT; immunological test strip device; Prevent ID CC).

faeces from different sites. If the test was not performed within 1 day of sample collection it was stored at 2–8 °C (as per the manufacturer's instructions). Two drops of this extracted sample were loaded into the sample opening of the test strip device, liquid faecal extract flows from the sample opening of the test device through the conjugate-release pad.

Principally it is a sandwich immunoassay in which gold-labelled anti-Hb antibodies bind to Hb (if present) in the sample. These complexes migrate over the test membrane until it passes the test zone, which consists of immobilized gold-labelled antibody–Hb complex and generates a violet band within 10 min (Figure 2a,b). To prevent false-negative an internal (control) line consisting of anti-IgG antibody has been added which indicates that the test has run properly. It has a very high sensitivity and can detect human Hb up to 10 g/mL.

The bedside FOBT was easy to use, and results did not depend on operator experience. All the three FOBTs were performed and reported by an experienced technician who was blinded to the patient's clinical profile.

Statistical analysis

For the statistical comparison of the non-parametrically distributed data, the Kruskal–Wallis ANOVA test was used (STATISTICA Version 5.0, StatSofts Inc., Tulsa, OK, USA). Sensitivity, specificity, positive predictive (PPV) and negative predictive (NPV) values of all the three FOBTs were determined.²⁵ Specificity was calculated for CR neoplasia as a whole group and not separately for adenoma and CRC. We used chi-square and Fisher's exact tests to compare differences in proportions amongst the tests. The *P*-values of <0.05 were considered as statistically significant (for sensitivity and specificity). Methods for proportions were used to calculate 95% confidence interval (CI).

RESULTS

A total of 387 consecutive patients underwent 407 tests, i.e. colonoscopies and FOBTs simultaneously. In 14 patients tests were repeated twice while in three patients they were repeated thrice. All the patients with repeat test were known cases of IBD. Their age ranged from 5 to 96 years (median age: 51 years). There was slight preponderance of females; 186 males and 201 females. The study duration was from January 2002 to December 2004. The major indications for colonoscopy were CRC screening, IBD, clinical suspicion of CR neoplasia or IBS, unexplained anaemia or diarrhoea, positive FOBT, etc. Comparative results of the test characteristics of asymptomatic screened patients and symptomatic patients are shown in Table 1. About 54 patients had evidence of CRC on colonoscopy (Table 2), the sensitivity of these tests to detect faecal Hb was 37.0%, 74.0% and 77.7% for the Guaiac-based test, the bedside IFOBT and the ELISA (cut-off <10 ng/mL) respectively (Table 3). Of 18 adenomas diagnosed, six were large (>10 mm) and 12 were small, i.e. <10 mm. The sensitivity of faecal Hb for any neoplasia (CR carcinoma plus large adenomas) was 29.1%, 59.7%, and 63.8% respectively (Table 3). Of 164 patients with normal colonic mucosa, 16 (9.7%) were positive with the Guaiac test, nine (5.5%) with the bedside IFOBT, whereas six (3.7%) were found positive with ELISA-IFOBT, i.e. false-positive.

About 141 (34.6%) patients revealed a lesion (bleeding) on colonoscopy which is fairly high when compared with screening population. This is because, ours was a hospital-based study, and mostly included symptomatic patients unlike the screening studies that usually includes asymptomatic healthy individuals. Active bleeding colonic lesions were found in 67 (43.2%) of total 155 IBD patients examined, 29 with

Figure 2. (a) Principle of the bedside immunochemical faecal occult blood test (IFOBT; immunological test strip device). After binding of faecal haemoglobin (blue dots) by antihaemoglobin antibodies, immunocomplexes are detected by a second nitrocellulose membrane-coupled anti-body, resulting in the appearance of a positive band. The formation of a control band indicates the correct function of the test and unimpeded flow of faecal extracts through the device. (b) Photograph of Prevent ID CC test strips from a faecal specimen negative or positive for faecal occult blood.




Table 1. Test characteristics in screening and symptomatic patients

Diagnosis	N	Positive Guaiac-based test, N (%)	Positive bedside IFOBT, N (%)	Positive ELISA-IFOBT, N (%)
Screening patients				
Colorectal neoplasia*	6	2 (33.3)	4 (66.7)	4 (66.7)
Normal	150	17 (11.4)	8 (5.3)	5 (3.3)
Total	156	19 (12.2)	12 (7.7)	9 (5.8)
Symptomatic patients/patients with known disease				
Colorectal neoplasia*	66	19 (28.8)	39 (59)	42 (63.6)
IBD	155	39 (25.2)	68 (43.9)	68 (43.9)
Others	30	3 (10)	3 (10)	3 (10)
Total	251	61 (24.3)	110 (43.8)	113 (45.0)

* CRC + large adenomas.

CRC, colorectal cancer; IFOBT, immunochemical faecal occult blood test; IBD, inflammatory bowel disease; ELISA, enzyme-linked immunosorbent assay.

ulcerative colitis (UC) and 38 with Crohn's disease (CD). About 88 patients had inactive IBD (i.e. no evidence of bleeding lesion during colonoscopy), 22 UC and 66 CD. Two patients with pseudomembranous colitis had all the three FOBTs-positive in them. Sensitivity and specificity of rapid bedside test was found to be statistically significant in detecting any bleeding lesion (except adenomas) when compared with Guaiac-based tests.

DISCUSSION

The CRC and adenomas bleed intermittently²⁶ and positivity of FOBTs depend on degree of blood loss. Generally 2 mL of blood is necessary in stool to produce positive Guaiac-based tests.⁵ When compared with CRC, adenomas bleed less frequently and also the bleeding is small in amount,²⁷ i.e. why sensitivity to detect them is lower. Also in the present study, the

Diagnosis	Total number	Positive Guaiac-based test, N (%)	Positive bedside IFOBT, N (%)	Positive ELISA-IFOBT, N (%)
Normal*	164	16 (9.7)	9 (5.5)	6 (3.7)
Colorectal cancer	54	20 (37.0)	40 (74.0)	42 (77.7)
Adenoma	18	1 (5.6)	3 (16.7)	4 (22.2)
Large (>10 mm)	6	1 (16.6)	2 (33.3)	3 (50.0)
Small (<10 mm)	12	0 (0)	0 (0)	0 (0)
IBD	155	39 (25.2)	68 (43.9)	68 (43.9)
UC	51			
Active	29	14 (48.3)	27 (93.1)	28 (96.6)
Inactive	22	2 (9.1)	1 (4.5)	1 (4.5)
CD	104			
Active	38	16 (42.1)	36 (94.7)	36 (94.7)
Inactive	66	7 (10.6)	4 (6.0)	3 (4.5)
Diverticulosis	10	2 (20)	0 (0)	0 (0)
Pseudomembranous colitis	2	2 (100)	2 (100)	2 (100)
Hyperplastic polyps	4	0 (0)	0 (0)	0 (0)

* Includes 13 patients with irritable bowel syndrome and 15 patients with unexplained diarrhoea.

IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn's disease; IFOBT, immunochemical faecal occult blood test; ELISA, enzyme-linked immunosorbent assay.

Table 2. Endoscopic diagnoses in 407 consecutive patients

Parameters	Guaiac-based test	Bedside IFOBT	ELISA-IFOBT
Sensitivity (%)			
Adenoma	5.56 (0.14–27.29)	18.9 (3.58–41.42)	22.2* (6.41–47.64)
Cancer	37.0 (24.29–51.26)	74.0* (60.35–85.04)	77.7* (64.40–87.96)
Cancer + adenoma	29.1 (19.05–41.07)	59.7* (47.50–71.12)	63.8* (51.71–74.88)
Ulcerative colitis	48.2 (29.45–67.47)	93.1 (77.23–99.15)	96.5 (82.24–99.91)
Crohn's disease	42.1 (26.31–59.18)	94.7* (82.25–99.36)	94.7* (82.25–99.36)
Specificity (%)			
Cancer + adenoma	90.2 (84.64–94.32)	94.5 (89.84–97.46)	96.3* (92.21–98.65)
Ulcerative colitis	90.9 (70.84–98.88)	95.4* (77.16–99.88)	95.4 (77.16–99.88)
Crohn's disease	89.3 (79.36–95.63)	93.9* (85.20–98.32)	95.4* (87.29–99.05)
PPV (%)			
Adenoma	5.9 (0.15–28.69)	25.0 (5.49–57.19)	40.0 (12.16–73.76)
Cancer	55.6 (38.10–72.06)	81.6 (67.98–91.24)	87.5 (74.75–95.27)
Cancer + adenoma	56.7 (39.49–72.90)	82.6 (69.67–91.77)	88.4 (76.56–95.65)
Ulcerative colitis	87.5 (61.65–98.45)	96.4 (81.65–99.91)	96.6 (82.24–99.91)
Crohn's disease	69.6 (47.08–86.79)	90.0 (76.34–97.21)	92.3 (79.13–98.38)
NPV (%)			
Adenoma	89.7 (84.02–93.88)	91.2 (85.86–94.98)	91.9 (86.72–95.48)
Cancer	81.3 (74.89–86.70)	91.7 (86.49–95.40)	92.9 (87.99–96.30)
Cancer + adenoma	74.4 (67.72–80.28)	84.2 (78.16–89.18)	85.9 (79.99–90.56)
Ulcerative colitis	57.1 (39.35–73.68)	91.3 (71.96–98.93)	95.4 (77.16–99.88)
Crohn's disease	72.8 (61.81–82.13)	96.9 (89.16–99.62)	96.7 (89.32–99.63)

* $P < 0.05$ compared with Guaiac-based test.

Values in parentheses indicate 95% CI.

IFOBT, immunochemical faecal occult blood test; PPV, positive predictive value; NPV, negative predictive value; ELISA, enzyme-linked immunosorbent assay; CI, confidence interval.

Table 3. Sensitivities, specificities, PPV and NPV of three FOBTs in the different diagnostic groups

sensitivity and specificity of all the three FOBTs performed were lowest for detecting adenomas when compared with all the other lesions.

The results of IFOBT performed on 1 day of stool sample has been shown to be almost as specific as Guaiac-based testing performed on 3 days of stool sample.²¹ We have also used 1-day stool sample for conducting FOBTs. Faecal Hb loses its antigenicity at room temperature mostly because of its degradation by faecal flora,²⁸ so we stored stool samples at 4 °C before testing.

One of the studies has demonstrated an increase in sensitivity by 7.4% but worsening of specificity by 7.3% with rehydration of stool sample with Guaiac-based tests.⁷ We also did not rehydrate the stool sample before performing the Guaiac-based test. There is a broad range of variation in the sensitivity of Guaiac-based tests. According to Ahlquist and Shuber in a review of eight prospective Guaiac-based tests against colonoscopy, in screening population, showed that sensitivity for diagnosing CRC was 26% while for large adenomas it was 12%.²⁹ We observed the sensitivity of Guaiac-based test for detecting CRC to be 37% and for large adenomas 16.6%. Although the specificity for Guaiac-based tests lies in the range of 88–98% actually it is misleading as false-positives outnumber the true positives. Only one in 10 subjects with a positive Guaiac-based test harbour a CRC.¹⁵ Thus, despite high specificity PPV is low.

The clinical value of technically comparable test strip devices for the rapid qualitative detection of other human proteins, e.g. cardiac troponin T or prostate-specific antigen, has already been proven.^{30, 31} Here, we have utilized the same principle for detection of FOB using an immunological test strip device.

We found the performance characteristics of the bedside IFOBT in detecting CRCs to be comparable with ELISA-IFOB. The sensitivity of this new bedside IFOBT for diagnosing CR neoplasia was 59.7% vs. 63.8% ($P = 0.29$) for ELISA-IFOB whereas the specificity of these two tests were 94.5 vs. 96.3 ($P = 0.38$) respectively. Thus, the sensitivity and specificity of bedside IFOBT was lower than that of ELISA-IFOB, but not statistically significant.

The sensitivity of both IFOBTs in the present study was in the same range or even better than that reported by other authors, and far higher than the values reported for Guaiac tests without rehydration.^{32, 33} A large screening study revealed sensitivity of IFOBT for detecting advanced neoplasia and cancer to be 27% and 66% respectively.²³

Upon comparison of rate of positive CR neoplasia in earlier large studies we noticed that the positivity rate of FOBT varied significantly (Table 4). These differences could be because of varied study populations and also inherent biases of these studies. As some of them were conducted in asymptomatic screening populations whereas others were performed in patients who were diseased. Also it is well evident that there is a wide range of variation in the rate of positivity of FOBT in detecting CR neoplasia, e.g. the range of HemOccult positivity is 47–84% while that of HemeSelect is 49–91%. Immunochemical tests were shown to be more sensitive than Guaiac-based tests.

In a study using a simple brush sampling technique for collection of stool for immunochemical 'Insure FOBT' demonstrated improved compliance by 66%. About 82% patients preferred brush over the

Table 4. Comparison of positive FOBTs in patients with CR neoplasia (CRC and adenoma >10 mm; modified from Ref.³²)

Reference	Lesions	Rate of positive lesions* (%)				
		HO	SENSA	HS	ELISA-IFOB	Bedside IFOBT
Ahlquist <i>et al.</i> ¹²	102	19	–	–	–	–
St John <i>et al.</i> ⁴⁴	152	75	84	91	–	–
Gopalswamy <i>et al.</i> ⁴⁵	9	60	78	89	–	–
Allison <i>et al.</i> ¹³	142	38	47	49	–	–
Greenberg <i>et al.</i> ³⁴	55	38	47	49	–	–
Our study	60	35	–	–	76	71

* Positive test in patients with lesion documented by endoscopy.

HO, HemOccult II; SENSA, HemOccult II SENSA; HS, HemeSelect; IFOBT, immunochemical faecal occult blood test; CRC, colorectal cancer; ELISA, enzyme-linked immunosorbent assay.

traditional sampling method using the spatula for performing FOBT.¹⁹ Similarly in this bedside IFOBT also the sample preparation is very simple with minimal stool handling, so we hope that it will improve patient acceptability for FOBTs.

Specificity is an important determinant of the cost of FOB screening. Even small changes in test specificity result in large effects on the number of false-positives in a screening study, which are responsible for unnecessary colonoscopic examinations. In our study the specificity defined by false-positive results if a normal colonic mucosa and no other cause of GI bleeding were shown to be between 89.3% and 90.9% for the Guaiac test, 93.9% and 95.4% for bedside IFOBT and 95.4% and 96.3% for the ELISA-IFOBT which is comparable with earlier reports in the literature.

One peculiar feature of our study is that subjects with variety of symptoms and with suspected or known clinical or endoscopic findings were included and underwent these tests. As the real focus of our work was to evaluate the relative performance characteristics of each of these three tests in diagnosing positive FOB irrespective of clinical diagnosis (whether because of CR neoplasia or active IBD) unlike previous studies which had excluded patients with known clinical diagnosis-like IBD, etc.^{34, 35} Non-malignant bleeding lesions were diagnosed in 69 of total 141 patients showing positive bleeding lesions on colonoscopy.

There are mainly two large reports in the literature mentioning diagnosis of IBD in patients undergoing FOBTs. Actually in these studies asymptomatic IBD were diagnosed upon performing colonoscopy in patients detected positive with FOBTs during CRC screening in large sample population.^{36, 37}

On comparing the costs of these tests, Guaiac-based FOBT costs around 1 €, ELISA-FOBT cost 15–20 € whereas for bedside IFOBT one has to pay 3–5 € for each test performed.

Newer promising non-invasive methods for CRC screening include detection of stool DNA for mutations-like p53, K-ras, APC, BAT-26, etc. However, initial enthusiasm with these tests could not be realized in large trials comparing it with Guaiac-based tests.^{38–41} The major drawbacks of it are lower sensitivities, exorbitant costs (up to 800\$), compliance issue as patient needs to send an entire bowel movement with a minimum weight of 30 g to be sent to the laboratory, which may not be acceptable to many patients and last but not the least anxiety associated with false-positive tests.

The inherent limitations of our study include, at first that a highly selected population undergoing colonoscopy for several 'high-risk' indications were included, and so care should be taken when applying our results to an average-risk asymptomatic population. Nevertheless, we feel that useful information was obtained about the feasibility and relative specificity of this new bedside IFOBT in our population. And secondly the use of endoscopy as the standard for the presence of bleeding lesion. Though colonoscopy is widely considered as the gold standard for detection of colonic bleeding lesions, miss rates of up to 6% in detection of adenomatous polyps are documented.^{42, 43} This might have caused underestimation of results of FOBT in our study.

The biggest advantages of this new bedside IFOBT are its simplicity, rapidity (needs just about 10 min), convenience, no need of cumbersome ELISA readers and the fact that it can be performed at the patient bedside or in doctor's office by any health care personnel. Thus, performing FOBT may become as simple as doing serum blood glucose determination using glucometer. This advance should make screening for CRC an attainable goal and should increase patient compliance.

To conclude, FOBT is the only method of CRC screening whose efficacy has been established in randomized-controlled trials. We have shown that the new bedside IFOBT, is more specific and appears to be more accurate than the Guaiac-based HemOccult test for the detection of significant colonic bleeding lesions including CR neoplasia. Although this constitutes a pilot study only, it provides some guidance as to which type of FOBT may be appropriate for large-scale screening programmes. Future larger-scale screening studies are required to evaluate it over a large asymptomatic sample size.

CONFLICT OF INTEREST

The authors have no conflicts of interest with the device manufacturers.

ACKNOWLEDGEMENTS

This work was supported by the Else Kröner-Fresenius-Foundation, Bad Homburg (Germany). Authors thank Mr Marc Neumann for helping with statistics. Also acknowledge the help rendered by Ms Maron Hagas and Ms Nada Povse for data management.

REFERENCES

- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; 55: 74–108.
- Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. *Ann Oncol* 2005; 16: 481–8.
- Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. *CA Cancer J Clin* 2005; 55: 10–30.
- Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. *JAMA* 2003; 289: 1288–96.
- Bresalier RS. Malignant neoplasms of the large intestine. In: Feldman, M, Friedman, LS, Sleisinger, MH, eds. *Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management*. Philadelphia, USA: W.B. Saunders, 2002: 2215–56.
- Allison JE. Review article: Faecal occult blood testing for colorectal cancer. *Aliment Pharmacol Ther* 1998; 12: 1–10.
- Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. *N Engl J Med* 1993; 328: 1365–71.
- Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal occult-blood screening for colorectal cancer. *Lancet* 1996; 348: 1472–7.
- Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. *Lancet* 1996; 348: 1467–71.
- Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. *Gastroenterology* 2004; 126: 1674–80.
- Allison JE, Feldman R, Tekawa IS. Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting. *Ann Intern Med* 1990; 112: 328–33.
- Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. *JAMA* 1993; 269: 1262–7.
- Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. *N Engl J Med* 1996; 334: 155–9.
- Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. *N Engl J Med* 2001; 345: 555–60.
- Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. *Am J Gastroenterol* 2005; 100: 1393–403.
- Macrae FA, St John DJ, Caligiore P. Optimal dietary conditions for Hemoccult testing. *Gastroenterology* 1982; 82: 899–903.
- Sieg A, Thoms C, Luthgens K, John MR, Schmidt-Gayk H. Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces. *Int J Colorectal Dis* 1999; 14: 267–71.
- Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M. Immunochemical versus Guaiac occult blood stool tests: results of a community-based screening program. *Surg Oncol* 1994; 3: 27–36.
- Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. *J Med Screen* 2003; 10: 117–22.
- Saito H, Soma Y, Koeda J, et al. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. *Int J Cancer* 1995; 61: 465–9.
- Castiglione G, Zappa M, Grazzini G, et al. Immunochemical vs Guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. *Br J Cancer* 1996; 74: 141–4.
- Nelson DB, McQuaid KR, Bond JH, Lieberman DA, Weiss DG, Johnston TK. Procedural success and complications of large-scale screening colonoscopy. *Gastrointest Endosc* 2002; 55: 307–14.
- Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. *Gastroenterology* 2005; 129: 422–8.
- Trojan J, Povse N, Schroder O, Stein J. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood. *Z Gastroenterol* 2002; 40: 921–4.
- Hulley SB, Cummings SR. *Designing Clinical Research*. Baltimore, USA: Williams & Wilkins, 1988.
- Ahlquist DA, McGill DB, Fleming JL, et al. Patterns of occult bleeding in asymptomatic colorectal cancer. *Cancer* 1989; 63: 1826–30.
- Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Owen RA. Fecal blood levels in health and disease. A study using HemoQuant. *N Engl J Med* 1985; 312: 1422–8.
- Saito H. Screening for colorectal cancer by immunochemical fecal occult blood testing. *Jpn J Cancer Res* 1996; 87: 1011–24.
- Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. *Clin Chim Acta* 2002; 315: 157–68.
- Lein M, Jung K, Schnorr D, Henke W, Loening SA. Strip test for the quick detection of increased concentrations of prostate-specific antigen in blood. *Eur J Clin Chem Clin Biochem* 1996; 34: 511–4.
- Muller-Bardorff M, Rauscher T, Kampmann M, et al. Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing. *Clin Chem* 1999; 45: 1002–8.
- Rozen P, Knaani J, Samuel Z. Eliminating the need for dietary restrictions when using a sensitive Guaiac fecal occult blood test. *Dig Dis Sci* 1999; 44: 756–60.
- Rozen P, Knaani J, Samuel Z. Comparative screening with a sensitive Guaiac and specific immunochemical occult blood test in an endoscopic study. *Cancer* 2000; 89: 46–52.
- Greenberg PD, Bertario L, Gnauck R, et al. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. *Am J Gastroenterol* 2000; 95: 1331–8.
- Wong BC, Wong WM, Cheung KL, et al. A sensitive Guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. *Aliment Pharmacol Ther* 2003; 18: 941–6.

- 36 Howarth GF, Robinson MH, Jenkins D, Hardcastle JD, Logan RF. High prevalence of undetected ulcerative colitis: data from the Nottingham fecal occult blood screening trial. *Am J Gastroenterol* 2002; **97**: 690–4.
- 37 Sakata T, Niwa Y, Goto H, *et al.* Asymptomatic inflammatory bowel disease with special reference to ulcerative colitis in apparently healthy persons. *Am J Gastroenterol* 2001; **96**: 735–9.
- 38 Ahlquist DA, Skoletsky JE, Boynton KA, *et al.* Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. *Gastroenterology* 2000; **119**: 1219–27.
- 39 Woolf SH. A smarter strategy? Reflections on fecal DNA screening for colorectal cancer. *N Engl J Med* 2004; **351**: 2755–8.
- 40 Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. *N Engl J Med* 2004; **351**: 2704–14.
- 41 Allison JE. Colon Cancer Screening Guidelines 2005: the fecal occult blood test option has become a better fit. *Gastroenterology* 2005; **129**: 745–8.
- 42 Hixson LJ, Fennerty MB, Sampliner RE, McGee D, Garewal H. Prospective study of the frequency and size distribution of polyps missed by colonoscopy. *J Natl Cancer Inst* 1990; **82**: 1769–72.
- 43 Rex DK, Cutler CS, Lemmel GT, *et al.* Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. *Gastroenterology* 1997; **112**: 24–8.
- 44 St John DJ, Young GP, Alexeyeff MA, *et al.* Evaluation of new occult blood tests for detection of colorectal neoplasia. *Gastroenterology* 1993; **104**: 1661–8.
- 45 Gopalswamy N, Stelling HP, Markert RJ, Maimon HN, Wahlen SD, Haddy RI. A comparative study of eight fecal occult blood tests and HemoQuant in patients in whom colonoscopy is indicated. *Arch Fam Med* 1994; **3**: 1043–8.